[go: up one dir, main page]

PE20100449A1 - Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas - Google Patents

Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas

Info

Publication number
PE20100449A1
PE20100449A1 PE2010000020A PE2010000020A PE20100449A1 PE 20100449 A1 PE20100449 A1 PE 20100449A1 PE 2010000020 A PE2010000020 A PE 2010000020A PE 2010000020 A PE2010000020 A PE 2010000020A PE 20100449 A1 PE20100449 A1 PE 20100449A1
Authority
PE
Peru
Prior art keywords
dysplasia
metaplasia
stains
detection
proliferative diseases
Prior art date
Application number
PE2010000020A
Other languages
English (en)
Inventor
Kai Licha
Michael Schirner
Martin Pessel
Malte Bahner
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100449(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20100449A1 publication Critical patent/PE20100449A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE CIANINA SF64, DE FORMULA (I) EN UNA CANTIDAD QUE PERMITE DETECTAR UNA ENFERMEDAD PROLIFERATIVA, CON UNA LESION PROLIFERATIVA DE 7mm DE DIAMETRO. DICHA CANTIDAD SE ADMINISTRA ENTRE 0.001 Y 0.5 mg/Kg DE PESO CORPORAL POR CADA APLICACION DE DIAGNOSTICO. REFIERE TAMBIEN QUE LA LESION PROLIFERATIVA ES: A) UNA PRECANCEROSIS TALES COMO QUERATOSIS ACTINICA, CUERNO CUTANEO, QUERATOSIS ACTINICA, ENTRE OTROS; B) UNA METAPLASIA TALES COMO UNA METAPLASIA MIELOIDE ANGIOGENICA, METAPLASIA APOCRINA, METAPLASIA ATIPICA, ENTRE OTROS; C) UNA DISPLASIA, TALES COMO DISPLASIA ECTODERMICA ANHIDROTICA, DISPLASIA ANTEROFACIAL, DISPLASIA TORACICA ASFIXIANTE; D) ENFERMEDAD OFTALMICA TALES COMO TRACOMA, RETINOPATIA DEL PREMATURO, GLAUCOMA NEOVASCULAR, ENTRE OTROS
PE2010000020A 2005-01-07 2006-01-05 Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas PE20100449A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05000276A EP1679082A1 (en) 2005-01-07 2005-01-07 Use of cyanine dyes for the diagnosis of proliferative diseases

Publications (1)

Publication Number Publication Date
PE20100449A1 true PE20100449A1 (es) 2010-07-25

Family

ID=34933224

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000039A PE20060872A1 (es) 2005-01-07 2006-01-05 Colorantes de cianina en el diagnostico de enfermedades proliferativas
PE2010000020A PE20100449A1 (es) 2005-01-07 2006-01-05 Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000039A PE20060872A1 (es) 2005-01-07 2006-01-05 Colorantes de cianina en el diagnostico de enfermedades proliferativas

Country Status (23)

Country Link
EP (2) EP1679082A1 (es)
JP (1) JP5578765B2 (es)
KR (1) KR20070092270A (es)
CN (1) CN101128218A (es)
AR (1) AR052190A1 (es)
AU (1) AU2006204496A1 (es)
BR (1) BRPI0606411A2 (es)
CA (1) CA2594390C (es)
CR (1) CR9232A (es)
DO (1) DOP2006000005A (es)
GT (1) GT200600001A (es)
IL (1) IL182499A0 (es)
MX (1) MX2007008300A (es)
NO (1) NO20074036L (es)
NZ (1) NZ554917A (es)
PA (1) PA8659101A1 (es)
PE (2) PE20060872A1 (es)
RU (1) RU2007129919A (es)
TW (1) TW200635612A (es)
UA (1) UA89976C2 (es)
UY (1) UY29323A1 (es)
WO (1) WO2006072580A1 (es)
ZA (1) ZA200706533B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374367T1 (de) * 2004-07-22 2007-10-15 Bayer Schering Pharma Ag Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
EP1743658A1 (en) * 2005-07-14 2007-01-17 Schering Aktiengesellschaft Optical imaging of rheumatoid arthritis
US20100119457A1 (en) * 2007-03-30 2010-05-13 Helmut Lenz Composition of labeled and non-labeled monoclonal antibodies
WO2009012109A2 (en) 2007-07-13 2009-01-22 Emory University Cyanine-containing compounds for cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
US20110085974A1 (en) * 2008-06-13 2011-04-14 Cedars-Sinai Medical Center Small molecule ligand-drug conjugates for targeted cancer therapy
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
SG177583A1 (en) 2009-07-09 2012-02-28 Hoffmann La Roche In vivo tumor vasculature imaging
WO2011012646A2 (en) 2009-07-28 2011-02-03 F. Hoffmann-La Roche Ag Non-invasive in vivo optical imaging method
AU2010286592B2 (en) 2009-08-28 2015-08-13 Visen Medical, Inc. Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique
JP2011046662A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
JP2011046663A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
CA2810822C (en) 2009-09-22 2018-03-06 Visen Medical, Inc. Systems and methods for virtual index-matching of diffusive media
JP6145404B2 (ja) 2010-05-07 2017-06-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エクスビボでの細胞の検出のための診断的方法
EP2683290B1 (en) 2011-03-07 2018-11-07 F.Hoffmann-La Roche Ag Methods for in vivo testing of therapeutic antibodies
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
KR101373108B1 (ko) 2012-01-20 2014-03-27 이화여자대학교 산학협력단 폴리메틴 체인에 메조-반응작용기를 갖는 신규한 시아닌 유도체 및 이의 제조방법
CN102608051B (zh) * 2012-02-21 2015-04-08 中国科学院化学研究所 用于诊断白血病的试剂盒
CN102706787B (zh) * 2012-05-24 2015-04-08 中国科学院化学研究所 菁染料的新用途
CN102703569B (zh) * 2012-05-24 2014-04-09 中国科学院化学研究所 菁染料的新用途
EP2906106B1 (en) 2012-10-15 2023-06-14 VisEn Medical, Inc. Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources
US20150182518A1 (en) 2012-10-26 2015-07-02 Canon Kabushiki Kaisha Cancer cell inhibitory drug and cancer stem-cell detection probe
WO2014092958A1 (en) * 2012-12-10 2014-06-19 Molecular Targeting Technologies, Inc. Compositions and methods of diagnosing ocular diseases
BR112016015198A2 (pt) 2013-12-31 2017-08-08 Memorial Sloan Kettering Cancer Center Sistemas, métodos e aparelho para a produção de imagens multicanal de fontes fluorescentes em tempo real
RU2565645C1 (ru) * 2014-09-05 2015-10-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ рентгендиагностики глубины инвазии рецидива рака вульвы в мягкие ткани
WO2016100340A1 (en) 2014-12-15 2016-06-23 Memorial Sloan Kettering Cancer Center Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging
KR20180093961A (ko) 2015-12-15 2018-08-22 메모리얼 슬로안-케터링 캔서 센터 조직 구별, 예를 들어, 수술 중 시각화를 위한 영상화 시스템 및 방법
CA3045007A1 (en) 2016-11-30 2018-06-07 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
CN111970960A (zh) 2018-03-30 2020-11-20 珀金埃尔默健康科学有限公司 使用短波红外(swir)投影层析成像对解剖器官和内含物进行3d重建的系统和方法
JP2022053289A (ja) * 2020-09-24 2022-04-05 大塚製薬株式会社 シアニン系色素、標識試薬および検出方法
EP4015004A1 (en) 2020-12-18 2022-06-22 Phi Pharma SA Proteoglycan specific branched peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
CA2514131A1 (en) * 2003-01-24 2004-08-05 Schering Ag Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis
ATE374367T1 (de) * 2004-07-22 2007-10-15 Bayer Schering Pharma Ag Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases

Also Published As

Publication number Publication date
DOP2006000005A (es) 2006-07-15
NZ554917A (en) 2010-01-29
CR9232A (es) 2007-11-23
PA8659101A1 (es) 2006-09-08
GT200600001A (es) 2006-08-22
AU2006204496A1 (en) 2006-07-13
TW200635612A (en) 2006-10-16
MX2007008300A (es) 2007-09-07
JP5578765B2 (ja) 2014-08-27
AR052190A1 (es) 2007-03-07
JP2008526802A (ja) 2008-07-24
CA2594390A1 (en) 2006-07-13
PE20060872A1 (es) 2006-10-01
NO20074036L (no) 2007-08-03
CA2594390C (en) 2013-10-22
BRPI0606411A2 (pt) 2009-06-23
CN101128218A (zh) 2008-02-20
ZA200706533B (en) 2009-07-29
UA89976C2 (ru) 2010-03-25
IL182499A0 (en) 2007-09-20
EP1833513B1 (en) 2013-03-06
EP1679082A1 (en) 2006-07-12
EP1833513A1 (en) 2007-09-19
UY29323A1 (es) 2006-10-02
RU2007129919A (ru) 2009-02-20
KR20070092270A (ko) 2007-09-12
WO2006072580A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
PE20100449A1 (es) Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas
AR050215A1 (es) Metodo para diagnosticar enfermedades utilizando copeptina.
Guo et al. Assessment of neuroprotection in the retina with DARC
US20180280342A1 (en) Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto
MX348859B (es) Agentes de contraste para formacion de imagenes por perfusion miocardial.
BRPI0608853B8 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
AR053579A1 (es) Tratamiento de la enfermedad inflamatoria intestinal (eii)
CR20120040A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
EP2822386A1 (en) Folate receptor alpha binding ligands
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
CR10842A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes
GT200500309A (es) Derivados de sulfonilbencilimidazol
SG152254A1 (en) Contrast agents for myocardial perfusion imaging
EA200801698A1 (ru) Лекарственные композиции для применения в вагине
BRPI0512209A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens de um corpo humano ou de animal por formação de imagem óptica, e de monitoração do efeito de tratamento de um corpo humano ou de animal com uma droga para combater uma condição associada com angiogênese
UY29245A1 (es) Combinaciones medicas
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
ECSP10010247A (es) Derivados heterocíclicos
UY29244A1 (es) Combinaciones medicas
PE20100742A1 (es) Nuevos procedimientos y formulaciones
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
PE20190608A1 (es) Composicion farmaceutica que comprende antagonista de receptor mineralocorticoide y su uso
ECSP067044A (es) Compuestos para el tratamiento de trastornos inflamatorios
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents

Legal Events

Date Code Title Description
FD Application declared void or lapsed